# Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

> **NCT03184571** · PHASE2 · COMPLETED · sponsor: **BerGenBio ASA** · enrollment: 99 (actual)

## Conditions studied

- Lung Cancer Metastatic
- NSCLC Stage IV
- Adenocarcinoma of Lung

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Bemcentinib

## Key facts

- **NCT ID:** NCT03184571
- **Lead sponsor:** BerGenBio ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-02
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184571, "Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03184571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*